These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30545832)

  • 1. How I treat MDS after hypomethylating agent failure.
    Santini V
    Blood; 2019 Feb; 133(6):521-529. PubMed ID: 30545832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
    Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.
    Uy N; Singh A; Gore SD; Prebet T
    Expert Opin Pharmacother; 2017 Aug; 18(12):1213-1224. PubMed ID: 28675065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.
    Lee P; Yim R; Yung Y; Chu HT; Yip PK; Gill H
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.
    Sohn SK; Moon JH; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Park SW; Lee WS; Lee SM; Kim H; Lee HS; Kim YS; Cho YY; Bae SH; Lee JH; Kim SH; Song IC; Kwon JH; Lee YJ
    Korean J Intern Med; 2018 Nov; 33(6):1194-1202. PubMed ID: 29232940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
    Steensma DP
    Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome.
    Modi D; Kim S; Singh V; Ayash L; Alavi A; Ratanatharathorn V; Uberti JP; Deol A
    Leuk Lymphoma; 2019 Nov; 60(11):2762-2770. PubMed ID: 31010370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.
    Zeidan AM; Kharfan-Dabaja MA; Komrokji RS
    Curr Opin Hematol; 2014 Mar; 21(2):123-30. PubMed ID: 24335709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
    Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
    Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents.
    Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S56-9. PubMed ID: 26297279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treating high-risk myelodysplastic syndromes].
    Adès L
    Bull Cancer; 2023 Nov; 110(11):1162-1167. PubMed ID: 37407322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypomethylating agent based combinations in higher risk myelodysplastic syndrome.
    Chandhok NS; Lewis R; Prebet T
    Leuk Lymphoma; 2020 May; 61(5):1012-1027. PubMed ID: 31814484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity.
    Madanat Y; Sekeres MA
    Semin Hematol; 2017 Jul; 54(3):147-153. PubMed ID: 28958288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
    Bewersdorf JP; Zeidan AM
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101245. PubMed ID: 33762100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndromes: Contemporary review and how we treat.
    Gangat N; Patnaik MM; Tefferi A
    Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
    Bewersdorf JP; Zeidan AM
    Leuk Lymphoma; 2020 Oct; 61(10):2295-2312. PubMed ID: 32421403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes.
    Kim Y; Kim IH; Kim HJ; Park S; Lee KH; Kim SJ; Lee JH; Kim DY; Yoon SS; Kim YK; Jang JH; Park SY; Ahn JS; Cheong CW; Lee JH; Cheong JW;
    Int J Hematol; 2014; 99(5):635-43. PubMed ID: 24648120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
    Zeidan AM; Salimi T; Epstein RS
    Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.